Skip to main content
. 2022 Aug 24;14(17):4103. doi: 10.3390/cancers14174103

Table 6.

KRAS scaffold inhibition (SHP2/SOS1), ongoing studies.

Title Status Condition Intervention NCT Number
SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation Recruiting
  • -

    NSCLC

  • -

    Solid Tumor
  • -

    BBP-398 with nivolumab

 NCT05375084
Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS-mutant Cancers (SHERPA) Recruiting
  • -

    Pancreatic Cancer

  • -

    CRC

  • -

    NSCLC

  • -

    KRAS Mutation-Related Tumors
  • -

    RMC-4630

  • -

    LY3214996

 NCT04916236
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies Recruiting
  • -

    NSCLC
  • -

    RMC-4630

  • -

    Sotorasib

 NCT05054725
Dose-Escalation/Expansion of RMC-4630 and Cobimetinib in Relapsed/Refractory Solid Tumors and RMC-4630 and Osimertinib in EGFR Positive Locally Advanced/Metastatic NSCLC Active, not recruiting
  • -

    Solid tumor
  • -

    RMC-4630

  • -

    Cobimetinib

  • -

    Osimertinib

 NCT03989115
A Phase 1 Study of the SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation Recruiting
  • -

    NSCLC

  • -

    Solid Tumor
  • -

    BBP-398 with Nivolumab

 NCT05375084
A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations Recruiting
  • -

    NSCLC

  • -

    CRC

  • -

    Pancreatic Cancer

  • -

    Solid Tumor
  • -

    HBI-2376

 NCT05163028
Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2) Active, not recruiting
  • -

    Advanced Cancer

  • -

    Metastatic Cancer

  • -

    Malignant Neoplastic Disease
  • -

    MRTX849

  • -

    TNO155

 NCT04330664
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (KontRASt-01) Recruiting
  • -

    KRAS G12C Mutant Solid Tumors

  • -

    NSCLC

  • -

    CRC
  • -

    JDQ443

  • -

    TNO155

  • -

    Tislelizumab

 NCT04699188

AC: AdenoCarcinoma; CRC: ColoRectal Cancer; NSCLC: Non-Small Cell Lung Cancer.